TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Treating younger patients with TAVR increases risk of death
Treating patients younger than 65 with TAVR is associated with certain risks for heart teams to consider. Fortunately, researchers found, care teams appear to be choosing patients wisely.
Cardiologist demand is on the rise—can hospitals keep up?
Demand for inpatient and outpatient cardiology services is expected to increase significantly in the next decade, putting hospitals and health systems in a position where they need to plan ahead or risk falling behind.
Self-expanding vs. balloon-expandable TAVR valves: How they compare after 5 years
SOLVE-TAVI focused on the long-term impact of selecting different second-generation transcatheter heart valves and anesthesia strategies for transfemoral TAVR procedures.
New data put a spotlight on troubling TAVR trends
Philippe Genereux, MD, principal investigator of the EARLY TAVR trial, noted that many patients with severe AS still go untreated.
Cardiologist behind EARLY TAVR explains how proactive treatment improves patient outcomes
Philippe Genereux, MD, principal investigator of the EARLY TAVR trial, discussed how a proactive treatment strategy for patients with asymptomatic AS can lead to better outcomes and improvements in quality of life.

SCAI 2021: Medtronic pleased with 30-day data on Evolut TAVR systems

Researchers presented 30-day data at the SCAI 2021 Scientific Sessions, highlighting the "excellent" outcomes and the importance of constantly working to improve patient care.

May 3, 2021

SCAI 2021: 98% of new TAVR programs developed in metropolitan areas

Researchers tracked 554 TAVR programs that opened from 2012 to 2018, sharing their findings at the SCAI 2021 Scientific Sessions.

April 29, 2021

Surgical risk scores may not be needed when considering TAVR

Recent TAVR research suggests clinicians should focus on other key factors such as the patient's age and life expectancy.

April 19, 2021

Risk of death, stroke increases with age for TAVR patients

The risk of post-TAVR pacemaker implantation also goes up when treating elderly patients.

April 14, 2021

COVID-19 patients undergoing TAVR may face a higher risk of death

The study included data from more than 3,000 TAVR patients who received care from January 2020 to January 2021.

April 14, 2021

Specialists complete first procedure in historic head-to-head TAVR study

The global trial is designed to compare TAVR systems from Medtronic and Edwards Lifesciences when treating patients with small annuli.

April 13, 2021

What TAVR availability has meant for patients with severe aortic stenosis

The impact on patients over the age of 65 has been undeniable.

April 2, 2021

How heart rhythm issues affect 2-year TAVR, SAVR outcomes

The study’s authors explored data from more than 900 low-risk patients who participated in the PARTNER 3 trial.

March 10, 2021

TAVR

Treating younger patients with TAVR increases risk of death

Cardiologist demand is on the rise—can hospitals keep up?

Self-expanding vs. balloon-expandable TAVR valves: How they compare after 5 years

New data put a spotlight on troubling TAVR trends

Cardiologist behind EARLY TAVR explains how proactive treatment improves patient outcomes